Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics


Fulcrum Therapeutics, Inc. (FULC): $12.93

0.31 (+2.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FULC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FULC POWR Grades

  • FULC scores best on the Sentiment dimension, with a Sentiment rank ahead of 70% of US stocks.
  • The strongest trend for FULC is in Growth, which has been heading up over the past 179 days.
  • FULC's current lowest rank is in the Stability metric (where it is better than 7.89% of US stocks).

FULC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FULC is 0.05 -- better than merely 10.99% of US stocks.
  • With a price/sales ratio of 61.26, FULCRUM THERAPEUTICS INC has a higher such ratio than 96.75% of stocks in our set.
  • Revenue growth over the past 12 months for FULCRUM THERAPEUTICS INC comes in at -41.54%, a number that bests merely 4.71% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to FULCRUM THERAPEUTICS INC are FUSN, CRDF, CDAK, VLN, and RXRX.
  • Visit FULC's SEC page to see the company's official filings. To visit the company's web site, go to www.fulcrumtx.com.

FULC Valuation Summary

  • FULC's EV/EBIT ratio is -5.5; this is 154.19% lower than that of the median Healthcare stock.
  • Over the past 43 months, FULC's price/earnings ratio has gone up 1.8.

Below are key valuation metrics over time for FULC.

Stock Date P/S P/B P/E EV/EBIT
FULC 2023-01-30 62.3 3 -6.2 -5.5
FULC 2023-01-27 62.5 3 -6.2 -5.5
FULC 2023-01-26 61.1 3 -6.1 -5.4
FULC 2023-01-25 62.5 3 -6.2 -5.5
FULC 2023-01-24 62.2 3 -6.2 -5.5
FULC 2023-01-23 61.4 3 -6.1 -5.4

FULC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FULC has a Quality Grade of D, ranking ahead of 14.4% of graded US stocks.
  • FULC's asset turnover comes in at 0.108 -- ranking 260th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FULC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.108 1 -1.792
2021-03-31 0.090 1 -1.731
2020-12-31 0.069 1 -1.552
2020-09-30 0.037 1 -2.003
2020-06-30 0.024 1 -2.355
2020-03-31 0.008 1 -3.830

FULC Price Target

For more insight on analysts targets of FULC, see our FULC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.86 Average Broker Recommendation 1.5 (Moderate Buy)

FULC Stock Price Chart Interactive Chart >

Price chart for FULC

FULC Price/Volume Stats

Current price $12.93 52-week high $24.79
Prev. close $12.62 52-week low $3.21
Day low $12.30 Volume 758,842
Day high $13.07 Avg. volume 1,195,386
50-day MA $8.83 Dividend yield N/A
200-day MA $7.63 Market Cap 673.02M

Fulcrum Therapeutics, Inc. (FULC) Company Bio


Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.


FULC Latest News Stream


Event/Time News Detail
Loading, please wait...

FULC Latest Social Stream


Loading social stream, please wait...

View Full FULC Social Stream

Latest FULC News From Around the Web

Below are the latest news stories about FULCRUM THERAPEUTICS INC that investors may wish to consider to help them evaluate FULC as an investment opportunity.

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 shares of its common stock at a public offering price of $13.00 per share. The gross proceeds to Fulcrum from the offering, before deducting underwriting discounts and commissions and other estimated o

Yahoo | January 18, 2023

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. Fulcrum also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the publi

Yahoo | January 17, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the Company’s common stock, pursuant to the Company’s 2022 Inducement Stock Incentive Plan, each as an inducement material to the new emplo

Yahoo | January 13, 2023

Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?

Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 11, 2023

Vince McMahon’s return to WWE: hedge funds and C-suites weekly

Here is your weekly roundup of the biggest news out of hedge funds and company top brass, all first covered on InvestingPro. World Wrestling Entertainment (NYSE:WWE) shares surged more than 16% on Friday after it was confirmed that the majority owner and former CEO Vince McMahon will be returning to the business and intends to undertake a review of the company’s strategic alternatives with the goal being to maximize value for all WWE shareholders. The move would be less than a year after McMahon retired following a sexual-harassment scandal.

Yahoo | January 8, 2023

Read More 'FULC' Stories Here

FULC Price Returns

1-mo 63.67%
3-mo 123.70%
6-mo 57.11%
1-year 13.82%
3-year -24.47%
5-year N/A
YTD 77.61%
2022 -58.85%
2021 51.07%
2020 -29.63%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7295 seconds.